UBS Group AG - STOKE THERAPEUTICS INC ownership

STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 96 filers reported holding STOKE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of STOKE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$1,597,612
+200.2%
118,254
+200.0%
0.00%
Q1 2024$532,103
+239.8%
39,415
+32.4%
0.00%
Q4 2023$156,606
+96.0%
29,773
+46.8%
0.00%
Q3 2023$79,884
-67.4%
20,275
-12.2%
0.00%
Q2 2023$245,351
+109.2%
23,081
+64.0%
0.00%
Q1 2023$117,262
-13.8%
14,077
-4.5%
0.00%
Q4 2022$136,032
+189.4%
14,738
+299.2%
0.00%
Q3 2022$47,000
-95.7%
3,692
-92.9%
0.00%
Q1 2022$1,093,000
+5.3%
51,941
+20.0%
0.00%
Q4 2021$1,038,000
+24.3%
43,277
+31.9%
0.00%
Q3 2021$835,000
+483.9%
32,813
+673.5%
0.00%
Q2 2021$143,000
-92.1%
4,242
-90.8%
0.00%
Q1 2021$1,799,000
+32.7%
46,315
+111.5%
0.00%
Q4 2020$1,356,000
+1256.0%
21,900
+400.0%
0.00%
Q1 2020$100,000
-61.4%
4,380
-52.1%
0.00%
Q4 2019$259,000
+97.7%
9,149
+50.6%
0.00%
Q3 2019$131,000
+197.7%
6,074
+299.6%
0.00%
Q2 2019$44,0001,5200.00%
Other shareholders
STOKE THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
RTW INVESTMENTS, LP 3,355,466$69,401,0004.13%
Cormorant Asset Management, LP 1,788,394$38,433,0002.34%
RA Capital Management 1,119,963$24,068,0001.43%
SPHERA FUNDS MANAGEMENT LTD. 346,380$7,384,0001.14%
Redmile Group, LLC 1,017,478$21,866,0000.73%
GILDER GAGNON HOWE & CO LLC 1,876,191$40,319,0000.46%
Perceptive Advisors 671,978$14,440,0000.39%
Casdin Capital, LLC 130,000$2,793,700,0000.29%
OXFORD ASSET MANAGEMENT LLP 116,196$2,497,0000.06%
Granite Point Capital Management, L.P. 17,000$365,0000.06%
View complete list of STOKE THERAPEUTICS INC shareholders